The benefit of sentinel lymph node biopsy in elderly patients with melanoma: A retrospective analysis of SEER Medicare data (2010-2018)
Sentinel lymph node status is critical for melanoma staging and treatment. However, the factors influencing SLNB and its oncologic benefits in elderly patients are unclear. We conducted a retrospective analysis of patients aged ≥65 with clinically node-negative melanoma and Breslow depth ≥1 mm, usi...
Gespeichert in:
| Veröffentlicht in: | The American journal of surgery 2024-11, Vol.237, p.115896 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 115896 |
| container_title | The American journal of surgery |
| container_volume | 237 |
| creator | Shen, Nathan Ramanathan, Siddharth Horns, Joshua J Hyngstrom, John R Bowles, Tawnya L Grossman, Douglas Asare, Elliot A |
| description | Sentinel lymph node status is critical for melanoma staging and treatment. However, the factors influencing SLNB and its oncologic benefits in elderly patients are unclear.
We conducted a retrospective analysis of patients aged ≥65 with clinically node-negative melanoma and Breslow depth ≥1 mm, using Surveillance, Epidemiology, and End Results Medicare database (2010-2018). Multivariable logistic regression assessed SLNB likelihood by demographic and clinical factors, and Cox-proportional hazard models evaluated overall and melanoma-specific mortality (MSM) for SLNB recipients versus non-recipients.
Of 13,160 melanoma patients, 62.29 % underwent SLNB. SLNB was linked to reduced all-cause mortality (HR: 0.65 [95%CI 0.61-0.70]) and MSM (HR: 0.76 [95%CI 0.67-0.85]). Older age, non-White race, male sex, and unmarried status was associated with decreased SLNB likelihood, while cardiopulmonary, neurologic, and secondary cancer comorbidities were associated with increased SLNB likelihood.
Though less frequently performed, SLNB is associated with lower mortality in elderly melanoma patients. Advanced age alone should not contraindicate SLNB. |
| doi_str_mv | 10.1016/j.amjsurg.2024.115896 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_3096278909</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3109787493</sourcerecordid><originalsourceid>FETCH-LOGICAL-p841-721856a5290c88a3c5b0ce2c2db588ac5ea96e2e8aea8d542fa4ebf8e9bb6f33</originalsourceid><addsrcrecordid>eNpdkMlKA0EQhhtRTIw-gtLgJR4m9jJLt7cQ4gIRweQeamZqTIfZ7J5R5gl8bTuoFy9V_NTHR1URcsnZjDMe3-5nUO1db99mgolwxnmkdHxExlwlOuBKyWMyZoyJQMecjciZc3sfOQ_lKRlJzRMZCT4mX5sd0hRrLExHm4I6rDtTY0nLoWp3tG5yPzZN6wZqaopljrYcaAud8aCjn6bb0QpLqJsK7uicWuxs41rMOvOBFGooB2fcwbxeLl_pM-YmA4s0hw7oVDDOAl_UzTk5KaB0ePHbJ2R9v9wsHoPVy8PTYr4KWhXyIBFcRTFEQrNMKZBZlLIMRSbyNPI5ixB0jAIVIKg8CkUBIaaFQp2mcSHlhEx_rK1t3nt03bYyLsPS749N77aS6VgkSjPt0et_6L7prb_HU5zpRCWhPgivfqk-rTDfttZUYIft34PlNzRyfwM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3109787493</pqid></control><display><type>article</type><title>The benefit of sentinel lymph node biopsy in elderly patients with melanoma: A retrospective analysis of SEER Medicare data (2010-2018)</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Shen, Nathan ; Ramanathan, Siddharth ; Horns, Joshua J ; Hyngstrom, John R ; Bowles, Tawnya L ; Grossman, Douglas ; Asare, Elliot A</creator><creatorcontrib>Shen, Nathan ; Ramanathan, Siddharth ; Horns, Joshua J ; Hyngstrom, John R ; Bowles, Tawnya L ; Grossman, Douglas ; Asare, Elliot A</creatorcontrib><description>Sentinel lymph node status is critical for melanoma staging and treatment. However, the factors influencing SLNB and its oncologic benefits in elderly patients are unclear.
We conducted a retrospective analysis of patients aged ≥65 with clinically node-negative melanoma and Breslow depth ≥1 mm, using Surveillance, Epidemiology, and End Results Medicare database (2010-2018). Multivariable logistic regression assessed SLNB likelihood by demographic and clinical factors, and Cox-proportional hazard models evaluated overall and melanoma-specific mortality (MSM) for SLNB recipients versus non-recipients.
Of 13,160 melanoma patients, 62.29 % underwent SLNB. SLNB was linked to reduced all-cause mortality (HR: 0.65 [95%CI 0.61-0.70]) and MSM (HR: 0.76 [95%CI 0.67-0.85]). Older age, non-White race, male sex, and unmarried status was associated with decreased SLNB likelihood, while cardiopulmonary, neurologic, and secondary cancer comorbidities were associated with increased SLNB likelihood.
Though less frequently performed, SLNB is associated with lower mortality in elderly melanoma patients. Advanced age alone should not contraindicate SLNB.</description><identifier>ISSN: 0002-9610</identifier><identifier>ISSN: 1879-1883</identifier><identifier>EISSN: 1879-1883</identifier><identifier>DOI: 10.1016/j.amjsurg.2024.115896</identifier><identifier>PMID: 39173521</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Age ; Biopsy ; Cancer ; Chronic obstructive pulmonary disease ; Comorbidity ; Epidemiology ; Ischemia ; Lymph nodes ; Lymphatic system ; Medical prognosis ; Medicare ; Melanoma ; Mortality ; Older people ; Patients ; Regression analysis ; Statistical models ; Surveillance ; Tumors ; Variables</subject><ispartof>The American journal of surgery, 2024-11, Vol.237, p.115896</ispartof><rights>Copyright © 2024 Elsevier Inc. All rights reserved.</rights><rights>2024. Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39173521$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shen, Nathan</creatorcontrib><creatorcontrib>Ramanathan, Siddharth</creatorcontrib><creatorcontrib>Horns, Joshua J</creatorcontrib><creatorcontrib>Hyngstrom, John R</creatorcontrib><creatorcontrib>Bowles, Tawnya L</creatorcontrib><creatorcontrib>Grossman, Douglas</creatorcontrib><creatorcontrib>Asare, Elliot A</creatorcontrib><title>The benefit of sentinel lymph node biopsy in elderly patients with melanoma: A retrospective analysis of SEER Medicare data (2010-2018)</title><title>The American journal of surgery</title><addtitle>Am J Surg</addtitle><description>Sentinel lymph node status is critical for melanoma staging and treatment. However, the factors influencing SLNB and its oncologic benefits in elderly patients are unclear.
We conducted a retrospective analysis of patients aged ≥65 with clinically node-negative melanoma and Breslow depth ≥1 mm, using Surveillance, Epidemiology, and End Results Medicare database (2010-2018). Multivariable logistic regression assessed SLNB likelihood by demographic and clinical factors, and Cox-proportional hazard models evaluated overall and melanoma-specific mortality (MSM) for SLNB recipients versus non-recipients.
Of 13,160 melanoma patients, 62.29 % underwent SLNB. SLNB was linked to reduced all-cause mortality (HR: 0.65 [95%CI 0.61-0.70]) and MSM (HR: 0.76 [95%CI 0.67-0.85]). Older age, non-White race, male sex, and unmarried status was associated with decreased SLNB likelihood, while cardiopulmonary, neurologic, and secondary cancer comorbidities were associated with increased SLNB likelihood.
Though less frequently performed, SLNB is associated with lower mortality in elderly melanoma patients. Advanced age alone should not contraindicate SLNB.</description><subject>Age</subject><subject>Biopsy</subject><subject>Cancer</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Comorbidity</subject><subject>Epidemiology</subject><subject>Ischemia</subject><subject>Lymph nodes</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Medicare</subject><subject>Melanoma</subject><subject>Mortality</subject><subject>Older people</subject><subject>Patients</subject><subject>Regression analysis</subject><subject>Statistical models</subject><subject>Surveillance</subject><subject>Tumors</subject><subject>Variables</subject><issn>0002-9610</issn><issn>1879-1883</issn><issn>1879-1883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpdkMlKA0EQhhtRTIw-gtLgJR4m9jJLt7cQ4gIRweQeamZqTIfZ7J5R5gl8bTuoFy9V_NTHR1URcsnZjDMe3-5nUO1db99mgolwxnmkdHxExlwlOuBKyWMyZoyJQMecjciZc3sfOQ_lKRlJzRMZCT4mX5sd0hRrLExHm4I6rDtTY0nLoWp3tG5yPzZN6wZqaopljrYcaAud8aCjn6bb0QpLqJsK7uicWuxs41rMOvOBFGooB2fcwbxeLl_pM-YmA4s0hw7oVDDOAl_UzTk5KaB0ePHbJ2R9v9wsHoPVy8PTYr4KWhXyIBFcRTFEQrNMKZBZlLIMRSbyNPI5ixB0jAIVIKg8CkUBIaaFQp2mcSHlhEx_rK1t3nt03bYyLsPS749N77aS6VgkSjPt0et_6L7prb_HU5zpRCWhPgivfqk-rTDfttZUYIft34PlNzRyfwM</recordid><startdate>20241101</startdate><enddate>20241101</enddate><creator>Shen, Nathan</creator><creator>Ramanathan, Siddharth</creator><creator>Horns, Joshua J</creator><creator>Hyngstrom, John R</creator><creator>Bowles, Tawnya L</creator><creator>Grossman, Douglas</creator><creator>Asare, Elliot A</creator><general>Elsevier Limited</general><scope>NPM</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20241101</creationdate><title>The benefit of sentinel lymph node biopsy in elderly patients with melanoma: A retrospective analysis of SEER Medicare data (2010-2018)</title><author>Shen, Nathan ; Ramanathan, Siddharth ; Horns, Joshua J ; Hyngstrom, John R ; Bowles, Tawnya L ; Grossman, Douglas ; Asare, Elliot A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p841-721856a5290c88a3c5b0ce2c2db588ac5ea96e2e8aea8d542fa4ebf8e9bb6f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Age</topic><topic>Biopsy</topic><topic>Cancer</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Comorbidity</topic><topic>Epidemiology</topic><topic>Ischemia</topic><topic>Lymph nodes</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Medicare</topic><topic>Melanoma</topic><topic>Mortality</topic><topic>Older people</topic><topic>Patients</topic><topic>Regression analysis</topic><topic>Statistical models</topic><topic>Surveillance</topic><topic>Tumors</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shen, Nathan</creatorcontrib><creatorcontrib>Ramanathan, Siddharth</creatorcontrib><creatorcontrib>Horns, Joshua J</creatorcontrib><creatorcontrib>Hyngstrom, John R</creatorcontrib><creatorcontrib>Bowles, Tawnya L</creatorcontrib><creatorcontrib>Grossman, Douglas</creatorcontrib><creatorcontrib>Asare, Elliot A</creatorcontrib><collection>PubMed</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shen, Nathan</au><au>Ramanathan, Siddharth</au><au>Horns, Joshua J</au><au>Hyngstrom, John R</au><au>Bowles, Tawnya L</au><au>Grossman, Douglas</au><au>Asare, Elliot A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The benefit of sentinel lymph node biopsy in elderly patients with melanoma: A retrospective analysis of SEER Medicare data (2010-2018)</atitle><jtitle>The American journal of surgery</jtitle><addtitle>Am J Surg</addtitle><date>2024-11-01</date><risdate>2024</risdate><volume>237</volume><spage>115896</spage><pages>115896-</pages><issn>0002-9610</issn><issn>1879-1883</issn><eissn>1879-1883</eissn><abstract>Sentinel lymph node status is critical for melanoma staging and treatment. However, the factors influencing SLNB and its oncologic benefits in elderly patients are unclear.
We conducted a retrospective analysis of patients aged ≥65 with clinically node-negative melanoma and Breslow depth ≥1 mm, using Surveillance, Epidemiology, and End Results Medicare database (2010-2018). Multivariable logistic regression assessed SLNB likelihood by demographic and clinical factors, and Cox-proportional hazard models evaluated overall and melanoma-specific mortality (MSM) for SLNB recipients versus non-recipients.
Of 13,160 melanoma patients, 62.29 % underwent SLNB. SLNB was linked to reduced all-cause mortality (HR: 0.65 [95%CI 0.61-0.70]) and MSM (HR: 0.76 [95%CI 0.67-0.85]). Older age, non-White race, male sex, and unmarried status was associated with decreased SLNB likelihood, while cardiopulmonary, neurologic, and secondary cancer comorbidities were associated with increased SLNB likelihood.
Though less frequently performed, SLNB is associated with lower mortality in elderly melanoma patients. Advanced age alone should not contraindicate SLNB.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>39173521</pmid><doi>10.1016/j.amjsurg.2024.115896</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9610 |
| ispartof | The American journal of surgery, 2024-11, Vol.237, p.115896 |
| issn | 0002-9610 1879-1883 1879-1883 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3096278909 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | Age Biopsy Cancer Chronic obstructive pulmonary disease Comorbidity Epidemiology Ischemia Lymph nodes Lymphatic system Medical prognosis Medicare Melanoma Mortality Older people Patients Regression analysis Statistical models Surveillance Tumors Variables |
| title | The benefit of sentinel lymph node biopsy in elderly patients with melanoma: A retrospective analysis of SEER Medicare data (2010-2018) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T00%3A40%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20benefit%20of%20sentinel%20lymph%20node%20biopsy%20in%20elderly%20patients%20with%20melanoma:%20A%20retrospective%20analysis%20of%20SEER%20Medicare%20data%20(2010-2018)&rft.jtitle=The%20American%20journal%20of%20surgery&rft.au=Shen,%20Nathan&rft.date=2024-11-01&rft.volume=237&rft.spage=115896&rft.pages=115896-&rft.issn=0002-9610&rft.eissn=1879-1883&rft_id=info:doi/10.1016/j.amjsurg.2024.115896&rft_dat=%3Cproquest_pubme%3E3109787493%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3109787493&rft_id=info:pmid/39173521&rfr_iscdi=true |